Financial Results
Galaxy Medicare Reports H1 FY27 Results
Galaxy Medicare approved unaudited standalone financial results for the half year ended September 30, 2026, along with the limited review report.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
3
Neutral
8
Bullish
3
Bearish
26
Neutral
13
Bullish
7
Bearish
23
Neutral
5
Bullish
4
Bearish
23
Neutral
5
Bullish
4
Bearish
23
Neutral
5
Bullish
4
Bearish
23
Neutral
5
Bullish
4
Healthcare Equipment & Supplies
Medical Equipment & Supplies
28 Cr
Low Risk
9.6
60.5
0.3
0.8
23.80
15.15
Sales CAGR
Profit CAGR
ROE
ROCE
Galaxy Medicare Ltd (GML) is currently trading at 17.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Galaxy Medicare Limited manufactures, brands, exports and trades medical devices, POP bandages, medical tapes, elastic bandages and surgical dressings through own brands, OEM production, institutional sales and international channels. The company has a particularly diversified route-to-market despite product concentration: OEM and contract manufacturing contributed 47.8% of FY26 revenue, while own brands, exports and trading, and institutional sales provided additional demand channels across domestic and international markets. Capacity is a clear near-term constraint and opportunity. POP Bandage utilisation reached 106% and Elastic Adhesive Bandage utilisation reached 91% in FY26, prompting machinery investment and a pre-cotton cleaning line for higher throughput and backward integration. Revenue increased from ₹312 million in FY23 to ₹400 million in FY26, but EBITDA declined from ₹49 million in FY24 to ₹43 million in FY26. This indicates that recent top-line growth has not translated into sustained operating-margin expansion. Exports rose steadily from ₹73 million in FY23 to ₹98 million in FY26, although Bangladesh accounts for approximately 83% of export sales. The company’s One Star Export House status and existing presence in the UK, Germany, Nepal and other markets provide a platform for geographic diversification.
Over the past 52 weeks, Galaxy Medicare Ltd has traded between a low of ₹15.15 and a high of ₹23.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Galaxy Medicare Ltd has a market capitalization of approximately 28.07. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Galaxy Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.58 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 28.07 Cr, Galaxy Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Galaxy Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Galaxy Medicare Ltd is 9.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Galaxy Medicare had Rs 8.4276 crore of working-capital IPO proceeds unspent as of September 30, 2026. It had used Rs 51.20 lakh from the Rs 8.9396 crore allocation. The deployed amount was recorded entirely against inventories.
Galaxy Medicare reported profit for the period of Rs 1.53 crore for the half year ended September 30, 2026. Profit was Rs 2.02 crore in the corresponding half year ended September 30, 2025, representing a decline of about 24%.
Galaxy Medicare reported standalone profit after tax of ₹1.53 crore for H1 FY27. This was 24.4% lower than the ₹2.02 crore reported in H1 FY26.